MIGRAINE: NEW THERAPEUTIC PERSPECTIVES. A NARRATIVE REVIEW
DOI:
https://doi.org/10.31435/ijitss.4(52).2026.6926Keywords:
Migraine, Acute Treatment, Preventive Treatment, Calcitonin Gene-Related Peptide, Pituitary Adenylate Cyclase-Activating Polypeptide, NeuromodulationAbstract
Migraine remains a major cause of disability despite the expanding range of acute and preventive treatments. This narrative review examines established and emerging pharmacological therapies alongside procedural and non-pharmacological interventions, with emphasis on clinical efficacy, tolerability and implications for individualised care. A defined collection of 64 publications, including randomised controlled trials, systematic reviews, meta-analyses and observational studies, was synthesised qualitatively without generating pooled estimates. Triptans remain effective acute treatments, whereas gepants and lasmiditan broaden the therapeutic options for patients with an insufficient response, poor tolerability or contraindications to vasoconstrictive agents. Their clinical utility depends on differences in administration, adverse effects and functional outcomes, including the central nervous system effects of lasmiditan. Calcitonin gene-related peptide pathway-targeting monoclonal antibodies and preventive gepants reduce migraine frequency, while onabotulinumtoxinA provides an established preventive option for chronic migraine. Targeting pituitary adenylate cyclase-activating polypeptide offers a biologically plausible additional strategy, although clinical findings remain heterogeneous and require confirmation. Neuromodulation, greater occipital nerve block, exercise, acupuncture and myofascial interventions may contribute to multimodal management, but the certainty and applicability of evidence vary substantially. Treatment selection should integrate migraine phenotype, comorbidities, previous treatment response and patient preferences. Further comparative trials and longer follow-up are needed to define optimal treatment sequencing, sustained effectiveness and the role of emerging approaches.
References
Eigenbrodt, A. K., Ashina, H., Khan, S., Diener, H., Mitsikostas, D. D., Sinclair, A. J., Pozo-Rosich, P., Martelletti, P., Ducros, A., Lantéri-Minet, M., Braschinsky, M., Del Rio, M. S., Daniel, O., Özge, A., Mammadbayli, A., Arons, M., Skorobogatykh, K., Romanenko, V., Terwindt, G. M.,... Ashina, M. (2021). Diagnosis and management of migraine in ten steps. Nature Reviews Neurology, 17(8), 501–514. https://doi.org/10.1038/s41582-021-00509-5
Puledda, F., Silva, E. M., Suwanlaong, K., & Goadsby, P. J. (2023). Migraine: From pathophysiology to treatment. Journal of Neurology, 270(7), 3654–3666. https://doi.org/10.1007/s00415-023-11706-1
Lu, W., Zhang, Y., Shi, C., et al. (2026). Migraine: Epidemiology, risk factors, pathophysiology, and treatment. MedComm, 7, e70933. https://doi.org/10.1002/mco2.70933
Dai, W., Liu, R., Qiu, E., Liu, Y., Chen, Z., Chen, X., Ao, R., Zhuo, M., & Yu, S. (2021). Cortical mechanisms in migraine. Molecular Pain, 17, 17448069211050246. https://doi.org/10.1177/17448069211050246
Atraszkiewicz, D. (2021). The processes underlying chronic migraine pathophysiology and its treatment with botulinum toxin type A. Neurology and Clinical Neuroscience, 9(6), 421–429. https://doi.org/10.1111/ncn3.12551
Deng, H., Li, G., Nie, H., Feng, Y., Guo, G., Guo, W., & Tang, Z. (2020). Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis. BMC Neurology, 20(1), 57. https://doi.org/10.1186/s12883-020-01633-3
Ashina, M., McAllister, P., Gaul, C., Leyva-Rendon, A., Ramirez, L. M., Nalpas, C., Thiry, A., Abraham, L., Fountaine, R. J., & Fullerton, T. (2025). Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trial. Cephalalgia, 45(11), 3331024251395298. https://doi.org/10.1177/03331024251395298
Ikeda, K., Matsumori, Y., Kudo, M., Ishikawa, T., Hoshino, Y., Yoshimatsu, H., Thiry, A., Arakawa, A., Croop, R., Fullerton, T., Sakai, F., & Takeshima, T. (2025). Efficacy and safety of rimegepant for the acute treatment of migraine in japan: A dose‐ranging, double‐blind, randomized controlled trial. Headache the Journal of Head and Face Pain, 65(10), 1811–1820. https://doi.org/10.1111/head.14994
Kudrow, D., Croop, R. S., Thiry, A., & Lipton, R. B. (2025). A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine. Headache the Journal of Head and Face Pain, 66(2), 407–416. https://doi.org/10.1111/head.15002
Croop, R., Madonia, J., Stock, D. A., Thiry, A., Forshaw, M., Murphy, A., Coric, V., & Lipton, R. B. (2022). Zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial. Headache the Journal of Head and Face Pain, 62(9), 1153–1163. https://doi.org/10.1111/head.14389
Deng, X., Zhou, L., Liang, C., Shang, X., Hui, X., Liu, W., Liang, S., Wang, Y., Xu, M., Guo, K., Yang, K., & Li, X. (2024). Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: Systematic review and network meta-analysis of randomised trials. The Journal of Headache and Pain, 25(1), 16. https://doi.org/10.1186/s10194-024-01723-4
Zhu, Z., Tang, Y., Li, L., Ni, H., Liu, M., Chen, Z., & Wang, Z. (2025). The efficacy and safety of zavegepant nasal inhalation versus oral calcitonin-gene related peptide receptor antagonists in the acute treatment of migraine: A systematic review and network meta-analysis of the literature. The Journal of Headache and Pain, 26(1), 48. https://doi.org/10.1186/s10194-025-01984-7
Ashina, M., Tepper, S. J., Reuter, U., Blumenfeld, A. M., Hutchinson, S., Xia, J., Miceli, R., Severt, L., Finnegan, M., & Trugman, J. M. (2023). Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial. Headache the Journal of Head and Face Pain, 63(1), 79–88. https://doi.org/10.1111/head.14439
Ailani, J., Lipton, R. B., Blumenfeld, A. M., Mechtler, L., Klein, B. C., He, M. Y., Smith, J. H., Trugman, J. M., De Abreu Ferreira, R., & Brand‐Schieber, E. (2024). Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the tandem study. Headache the Journal of Head and Face Pain, 65(6), 1005–1014. https://doi.org/10.1111/head.14871
Messina, R., Huessler, E., Puledda, F., Haghdoost, F., Lebedeva, E. R., & Diener, H. (2023). Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis. Cephalalgia, 43(3), 3331024231152169. https://doi.org/10.1177/03331024231152169
Yu, S., Matsumori, Y., Kim, B., Gryglas-Dworak, A., Giorgadze, G., Pozo-Rosich, P., Josiassen, M. K., Ranc, K., Ettrup, A., Mittoux, A., Sperling, B., & Takeshima, T. (2025). Efficacy and safety of eptinezumab in a predominantly asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled sunrise trial. Cephalalgia, 45(10), 3331024251386095. https://doi.org/10.1177/03331024251386095
Huang, I., Wu, P., Lee, Y., & Kang, Y. (2020). Optimal treatment strategy of fremanezumab in migraine prevention: A systematic review with network meta-analysis of randomized clinical trials. Scientific Reports, 10(1), 18609. https://doi.org/10.1038/s41598-020-75602-8
Han, L., Liu, Y., Xiong, H., & Hong, P. (2019). CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis. Brain and Behavior, 9(2), e01215. https://doi.org/10.1002/brb3.1215
Zhao, X., Xu, X., & Li, Q. (2020). Efficacy and safety of galcanezumab for preventive treatment of migraine: A systematic review and meta-analysis. Journal of Neurology, 268(7), 2364–2376. https://doi.org/10.1007/s00415-020-09707-5
Puledda, F., Younis, S., Huessler, E., Haghdoost, F., Lisicki, M., Goadsby, P. J., & Tassorelli, C. (2023). Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature. Cephalalgia, 43(3), 3331024231151419. https://doi.org/10.1177/03331024231151419
Laohapiboolrattana, W., Jansem, P., Anukoolwittaya, P., Roongpiboonsopit, D., Hiransuthikul, A., Pongpitakmetha, T., Thanprasertsuk, S., & Rattanawong, W. (2024). Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: Systematic review and network meta-analysis. The Journal of Headache and Pain, 25(1), 194. https://doi.org/10.1186/s10194-024-01904-1
Hou, M., Xing, H., Li, C., Wang, X., Deng, D., Li, J., Zhang, P., & Chen, J. (2020). Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: A systematic review and meta-analysis. The Journal of Headache and Pain, 21(1), 66. https://doi.org/10.1186/s10194-020-01138-x
Karlsson, W. K., Ostinelli, E. G., Zhuang, Z. A., Kokoti, L., Christensen, R. H., Al-Khazali, H. M., Deligianni, C. I., Tomlinson, A., Ashina, H., De La Torre, E. R., Diener, H., Cipriani, A., & Ashina, M. (2024). Comparative effects of drug interventions for the acute management of migraine episodes in adults: Systematic review and network meta-analysis. BMJ, 386, e080107. https://doi.org/10.1136/bmj-2024-080107
Yang, C., Liang, C., Chang, C., Yang, C., Shih, P., Yau, Y., Tang, K., & Wang, S. (2021). Comparison of new pharmacologic agents with triptans for treatment of migraine. JAMA Network Open, 4(10), e2128544. https://doi.org/10.1001/jamanetworkopen.2021.28544
Leroux, E., Buchanan, A., Lombard, L., Loo, L. S., Bridge, D., Rousseau, B., Hopwood, N., Matthews, B. R., & Reuter, U. (2020). Evaluation of patients with insufficient efficacy and/or tolerability to triptans for the acute treatment of migraine: A systematic literature review. Advances in Therapy, 37(12), 4765–4796. https://doi.org/10.1007/s12325-020-01494-9
Lipton, R. B., Gendolla, A., Abraham, L., Jenkins, A., Telfort, J., Blakeman, K. H., Saccone, P. A., Pustulka, I., Fotheringham, I., & Engh, A. (2024). Relative frequency, characteristics, and disease burden of patients with migraine unsuitable for triptan treatment: A systematic literature review. Headache the Journal of Head and Face Pain, 65(1), 164–179. https://doi.org/10.1111/head.14854
Whealy, M., & Becker, W. J. (2024). The 5-HT1B and 5-HT1D agonists in acute migraine therapy: Ergotamine, dihydroergotamine, and the triptans. Handb Clin Neurol, 199, 17-42. https://doi.org/10.1016/B978-0-12-823357-3.00008-2
Bigal, M. E., & Tepper, S. J. (2003). Ergotamine and dihydroergotamine: A review. Current Pain and Headache Reports, 7(1), 55–62.
Mitsikostas, D. D., & Ward, T. N. (2024). Evidence-based symptomatic treatment of migraine. Handb Clin Neurol, 199, 203-218. https://doi.org/10.1016/B978-0-12-823357-3.00004-5
Koehler, P. J., & Boes, C. J. (2023). History of migraine. Handb Clin Neurol, 198, 3-21. https://doi.org/10.1016/B978-0-12-823356-6.00002-0
Ngo, M., & Patel, P. (2026, June 8). Ergotamine/caffeine. In StatPearls. StatPearls Publishing.
Terpening, C. M., & Wietholter, J. P. (2025). Dihydroergotamine intranasal powder for acute migraine treatment. Annals of Pharmacotherapy, Advance online publication.
Silvestro, M., Orologio, I., Tessitore, A., Trojsi, F., Tedeschi, G., & Russo, A. (2024). Dihydroergotamine mesylate nasal spray: An acute treatment option for migraine in adults. Expert Rev Neurother, 24(6), 555-564. https://doi.org/10.1080/14737175.2024.2342446
Cooper, W., Ray, S., Aurora, S. K., Shrewsbury, S. B., Fuller, C., Davies, G., & Hoekman, J. (2022). Delivery of dihydroergotamine mesylate to the upper nasal space for the acute treatment of migraine: Technology in action. J Aerosol Med Pulm Drug Deliv, 35(6), 321-332. https://doi.org/10.1089/jamp.2022.0005
Tynan, D., Ahmad, K., & Thieben, M. (2018). Long-term ergotamine derivative therapy for migraine associated with pachymeningitis and sixth cranial nerve palsy. Neuro-Ophthalmology, 44(2), 117–121.
Rubio-Beltrán, E., Correnti, E., Deen, M., Kamm, K., Kelderman, T., Papetti, L., Vigneri, S., MaassenVanDenBrink, A., & Edvinsson, L. (2018). PACAP38 and PAC1 receptor blockade: A new target for headache? The journal of headache and pain, 19(1), 64. https://doi.org/10.1186/s10194-018-0893-8
Kuburas, A., & Russo, A. F. (2023). Shared and independent roles of CGRP and PACAP in migraine pathophysiology. The Journal of Headache and Pain, 24(1), 34. https://doi.org/10.1186/s10194-023-01569-2
Al-Karagholi, M. A., Zhuang, Z. A., Beich, S., Ashina, H., & Ashina, M. (2025). PACAP38-induced migraine attacks are independent of CGRP signaling: A randomized controlled trial. The Journal of Headache and Pain, 26(1), 79. https://doi.org/10.1186/s10194-025-02022-2
Johnson, M. P., Krikke-Workel, J., Patel, C. N., Morin, S. M., Turner, P. K., Clark, K. A., Donley, D., Jin, Y., Johnson, K. W., Vincent, M., Stille, J. R., Broad, L. M., & Patel, A. (2025). Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine. Cephalalgia, 45(8), 3331024251368757. https://doi.org/10.1177/03331024251368757
Shaterian, N., Shaterian, N., Ghanaatpisheh, A., Abbasi, F., Daniali, S., Jahromi, M. J., Sanie, M. S., & Abdoli, A. (2022). Botox (onabotulinumtoxinA) for treatment of migraine symptoms: A systematic review. Pain research & management, 2022, 3284446. https://doi.org/10.1155/2022/3284446
Turkel, C. C., Aurora, S., Diener, H. C., Dodick, D. W., Lipton, R. B., Silberstein, S. D., & Brin, M. F. (2023). Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact. Medicine, 102(S1), e32600. https://doi.org/10.1097/MD.0000000000032600
Lanteri-Minet, M., Ducros, A., Francois, C., Olewinska, E., Nikodem, M., & Dupont-Benjamin, L. (2022). Effectiveness of onabotulinumtoxinA (Botox®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data. Cephalalgia: an international journal of headache, 42(14), 1543–1564. https://doi.org/10.1177/03331024221123058
Yuan, H., Orr, S. L., Al-Karagholi, M. A. M., Ashina, M., Cohen, F., Diener, H. C., Dodick, D. W., Jensen, R. H., Marmura, M. J., Martinelli, D., Matharu, M. S., Petersen, A. S., Pozo-Rosich, P., Sacco, S., Simmonds, L., Tassorelli, C., Tepper, S. J., Terwindt, G. M., Wang, S. J., Yeh, J. T., … Silberstein, S. D. (2025). International headache society evidence-based guidelines on the use of non-invasive neuromodulation devices for the acute and preventive treatment of migraine. Cephalalgia: an international journal of headache, 45(10), 3331024251388377. https://doi.org/10.1177/03331024251388377
Reuter, U., McClure, C., Liebler, E., & Pozo-Rosich, P. (2019). Non-invasive neuromodulation for migraine and cluster headache: A systematic review of clinical trials. Journal of neurology, neurosurgery, and psychiatry, 90(7), 796–804. https://doi.org/10.1136/jnnp-2018-320113
Fernández-Hernando, D., Fernández-de-Las-Peñas, C., Pareja-Grande, J. A., García-Esteo, F. J., & Mesa-Jiménez, J. A. (2023). Management of auricular transcutaneous neuromodulation and electro-acupuncture of the vagus nerve for chronic migraine: A systematic review. Frontiers in neuroscience, 17, 1151892. https://doi.org/10.3389/fnins.2023.1151892
Canales-Rodríguez, J., Angerhöfer, C., Caronna, E., Raffaelli, B., Overeem, L. H., Pozo-Rosich, P., & Reuter, U. (2026). Efficacy, IHS guideline adherence, and methodological quality of noninvasive neuromodulation clinical trials in migraine and cluster headache: A systematic review. European journal of neurology, 33(6), e70559. https://doi.org/10.1111/ene.70559
Atraszkiewicz, D., Ünal, E., Bassett, P., Morell-Ducos, F., & Bahra, A. (2025). Greater occipital nerve block for the treatment of migraine: An umbrella review, systematic review, and meta-analysis. Cephalalgia: an international journal of headache, 45(12), 3331024251398390. https://doi.org/10.1177/03331024251398390
Tamayo de Leon, C. D., Gama-Reyes, E. G., Paredes Moreno, F. A., & Galnares-Olalde, J. A. (2025). Adjunctive occipital nerve block for emergency treatment of acute migraine: A randomized, controlled trial. Cephalalgia: an international journal of headache, 45(10), 3331024251381764. https://doi.org/10.1177/03331024251381764
Sabet, H., Abbas, A., Abouelmagd, M. E., Samir, A., Helal, M. M., El-Moslemani, M., Younis, A. F., Yousef, O., Rouby, R. A., & Abd-Elsayed, A. (2025). Ultrasound-guided greater occipital nerve block for chronic migraine: A systematic review and meta-analysis. Head & face medicine, 21(1), 81. https://doi.org/10.1186/s13005-025-00554-1
Nasir, R., Baig, M. O., Abualait, T., Obaid, S., Jadoon, I. J., Al-Hussain, F., & Bashir, S. (2026). Effects of vagal nerve stimulation on pain frequency and intensity in chronic migraine in adults: A randomized controlled trial. Physiological reports, 14(7), e70843. https://doi.org/10.14814/phy2.70843
Farahani, A., Adel Ghahraman, M., Togha, M., Malmir, K., & Jalaie, S. (2026). Effects of adding transcutaneous vagus nerve stimulation to vestibular rehabilitation on dizziness and postural control in vestibular migraine: A randomized clinical trial. Scientific reports, 16(1), 8133. https://doi.org/10.1038/s41598-026-39697-9
Diener, H. C., Goadsby, P. J., Ashina, M., Al-Karagholi, M. A., Sinclair, A., Mitsikostas, D., Magis, D., Pozo-Rosich, P., Irimia Sieira, P., Làinez, M. J., Gaul, C., Silver, N., Hoffmann, J., Marin, J., Liebler, E., & Ferrari, M. D. (2019). Non-invasive vagus nerve stimulation (nvns) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled premium trial. Cephalalgia: an international journal of headache, 39(12), 1475–1487. https://doi.org/10.1177/0333102419876920
VanderPluym, J. H., Halker Singh, R. B., Urtecho, M., Morrow, A. S., Nayfeh, T., Torres Roldan, V. D., Farah, M. H., Hasan, B., Saadi, S., Shah, S., Abd-Rabu, R., Daraz, L., Prokop, L. J., Murad, M. H., & Wang, Z. (2021). Acute treatments for episodic migraine in adults: A systematic review and Meta-analysis. JAMA, 325(23), 2357–2369. https://doi.org/10.1001/jama.2021.7939
Rezaeian, T., Ahmadi, M., Mosallanezhad, Z., & Nourbakhsh, M. R. (2021). The impact of myofascial release and stretching techniques on the clinical outcomes of migraine headache. Journal of Research in Medical Sciences, 26, 45.
Jara Silva, C. E., Joseph, A. M., Khatib, M., Knafo, J., Karas, M., Krupa, K., Rivera, B., Macia, A., Madhu, B., McMillan, M., Burtch, J., Quinonez, J., Albert, T., & Khanna, D. (2022). Osteopathic manipulative treatment and the management of headaches: A scoping review. Cureus, 14(8), e27830. https://doi.org/10.7759/cureus.27830
Pillai, S., & Zhang, N. (2023). The role of manual therapies in the treatment of headache disorders. Curr Neurol Neurosci Rep, 23(8), 399-405. https://doi.org/10.1007/s11910-023-01279-x
Lu, Z., Zou, H., Zhao, P., Wang, J., & Wang, R. (2024). Myofascial release for the treatment of tension-type, cervicogenic headache or migraine: A systematic review and Meta-Analysis. Pain Research and Management, 2024, 2042069.
Lv, Y., & Yin, Y. (2024). A review of the application of myofascial release therapy in the treatment of diseases. Journal of Multidisciplinary Healthcare, 17, 4507–4517.
Lemmens, J., De Pauw, J., Van Soom, T., et al. (2019). The effect of aerobic exercise on the number of migraine days, duration and pain intensity in migraine: A systematic literature review and meta-analysis. J Headache Pain, 20(1), 16. https://doi.org/10.1186/s10194-019-0961-8
Woldeamanuel, Y. W., & Oliveira, A. B. D. (2022). What is the efficacy of aerobic exercise versus strength training in the treatment of migraine? A systematic review and network meta-analysis of clinical trials. J Headache Pain, 23(1), 134. https://doi.org/10.1186/s10194-022-01503-y
Liu, L., Chen, Q., Zhao, L., Lyu, T., Nie, L., Miao, Q., Liu, Y., Zheng, L., Fu, F., Luo, Y., Zeng, C., Zhang, C., Peng, P., Zhang, Y., & Li, B. (2024). Acupuncture plus topiramate placebo versus topiramate plus sham acupuncture for the preventive treatment of chronic migraine: A single-blind, double-dummy, randomized controlled trial. Cephalalgia: an international journal of headache, 44(6), 3331024241261080. https://doi.org/10.1177/03331024241261080
Lu, T., Yang, Y., Li, J., Lu, L., & Liu, J. (2025). Acupuncture improves migraine and quality of life in patients with migraine: A systematic review with meta-analysis. Systematic reviews, 14(1), 220. https://doi.org/10.1186/s13643-025-02977-y
Zhang, X., Chen, Q., Liu, Y., Li, J., Nie, L., Miao, Q., Fu, F., Lyu, T., Tan, Z., Kong, Y., Li, B., & Liu, L. (2026). Acupuncture for migraine without aura and connection-based efficacy prediction: A randomized clinical trial. JAMA network open, 9(1), e2555454. https://doi.org/10.1001/jamanetworkopen.2025.55454
Pistoia, F., Cesarano, S., Saporito, G., Albanese, M., Lucenti, C., Scarsella, S., Liguori, A., & Ronchi, F. U. (2025). Acupuncture versus standard medical care in the prophylactic treatment of migraine: A systematic review and Meta-Analysis. European journal of neurology, 32(4), e70160. https://doi.org/10.1111/ene.70160
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Magdalena Ślifierska, Kamil Rutkowski, Julia Kulesza, Paulina Kwiecień, Anton Osnytskyy, Jan Mianowski, Daria Furman, Agata Zielińska

This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.

